Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.38 USD
+0.01 (0.30%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $3.39 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Repare Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 224 | 344 | 342 | 334 | 95 |
Receivables | 15 | 4 | 3 | 6 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 6 | 6 | 7 | 1 |
Total Current Assets | 244 | 354 | 351 | 347 | 99 |
Net Property & Equipment | 4 | 4 | 6 | 4 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 4 | 1 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 1 | 1 | 1 |
Total Assets | 254 | 364 | 369 | 357 | 103 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 0 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 22 | 19 | 6 | 1 |
Income Taxes Payable | 0 | 1 | 1 | 0 | 0 |
Other Current Liabilities | 10 | 53 | 12 | 2 | 0 |
Total Current Liabilities | 39 | 79 | 35 | 11 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 3 | 40 | 56 | 8 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 42 | 85 | 80 | 70 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 136 |
Common Stock (Par) | 483 | 482 | 481 | 384 | 0 |
Capital Surplus | 62 | 37 | 18 | 6 | 4 |
Retained Earnings | -333 | -239 | -210 | -103 | -50 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 212 | 280 | 288 | 287 | 90 |
Total Liabilities & Shareholder's Equity | 254 | 364 | 369 | 357 | 103 |
Total Common Equity | 212 | 280 | 288 | 287 | -46 |
Shares Outstanding | 42.10 | 41.90 | 41.70 | 36.70 | NA |
Book Value Per Share | 5.04 | 6.67 | 6.92 | 7.82 | 0.00 |
Fiscal Year End for Repare Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 208 | 237 | 224 | 250 | 281 |
Receivables | 15 | 14 | 15 | 19 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 3 | 5 | 6 | 4 |
Total Current Assets | 229 | 255 | 244 | 275 | 292 |
Net Property & Equipment | 3 | 4 | 4 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1 | 2 | 2 | 2 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 235 | 263 | 254 | 286 | 302 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 7 | 2 | 5 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 22 | 20 | 24 | 21 | 22 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 10 | 20 | 24 |
Total Current Liabilities | 31 | 31 | 39 | 49 | 53 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 2 | 2 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 32 | 31 | 42 | 53 | 56 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 486 | 486 | 483 | 483 | 483 |
Capital Surplus | 72 | 66 | 62 | 56 | 49 |
Retained Earnings | -355 | -320 | -333 | -305 | -286 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 204 | 232 | 212 | 233 | 245 |
Total Liabilities & Shareholder's Equity | 235 | 263 | 254 | 286 | 302 |
Total Common Equity | 204 | 232 | 212 | 233 | 245 |
Shares Outstanding | 42.40 | 42.40 | 42.10 | 42.00 | 42.00 |
Book Value Per Share | 4.80 | 5.47 | 5.04 | 5.56 | 5.84 |